Zealand Pharma reported a quarterly loss of $0.87 per share, beating the Zacks Consensus Estimate for a loss of $1.57 by $0.70 per share. The result also improved from a loss of $0.67 per share a year ago, indicating better-than-expected earnings performance despite remaining unprofitable. The headline is likely modestly supportive for the stock, but the article provides no revenue or guidance details.
Zealand Pharma reported a quarterly loss of $0.87 per share, beating the Zacks Consensus Estimate for a loss of $1.57 by $0.70 per share. The result also improved from a loss of $0.67 per share a year ago, indicating better-than-expected earnings performance despite remaining unprofitable. The headline is likely modestly supportive for the stock, but the article provides no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.38
